Company profile: NEO New Oncology
1.1 - Company Overview
Company description
- Provider of the NEO diagnostic platform, designed and developed by NEO New Oncology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NEO New Oncology
AltheaDx
HQ: United States
Website
- Description: Provider of molecular diagnostics and PCR-based services, including molecular biomarker discovery, assay development and validation, prospective/retrospective clinical trial testing, and gene expression and genotyping analysis for pre-clinical and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AltheaDx company profile →
ProQR
HQ: The Netherlands
Website
- Description: Provider of RNA therapeutics and editing platforms for severe genetic rare diseases. Develops Axiomer RNA base-editing technology and Trident pseudouridylation platform, with programs AX-0810 for cholestatic diseases and AX-1412 for cardiovascular diseases, and product candidates QR-010, QR-110, and QR-313 for cystic fibrosis, Leber's congenital amaurosis type 10, and dyastrophic epidermolysis bullosa; partners with Eli Lilly.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProQR company profile →
Intellia Therapeutics
HQ: United States
Website
- Description: Provider of genome editing therapies developing curative gene-editing treatments, including CRISPR-based candidates NTLA-2001 for transthyretin amyloidosis via single intravenous in vivo gene editing and NTLA-2002 for hereditary angioedema by editing KLKB1 to reduce kallikrein activity. Offers in vivo CRISPR platform using lipid nanoparticles and ex vivo platform engineering T cells for oncological and immunological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intellia Therapeutics company profile →
Siolta Therapeutics
HQ: United States
Website
- Description: Provider of therapeutic microbial consortia and live biotherapeutic products to prevent and treat inflammatory and atopic diseases. Offers the Precision Symbiotics Platform integrating clinical data, bioinformatics, and microbial science; STMC-103H in phase 2 for atopic disease prevention; maternal-infant axis therapeutics; diagnostics for patient stratification; and GMP manufacturing for clinical advancement.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Siolta Therapeutics company profile →
Inflammatix
HQ: United States
Website
- Description: Provider of rapid immune system diagnostics and sepsis-focused research. Offers the TriVerity Acute Infection and Sepsis Test System—Myrna Instrument and TriVerity Test—to identify bacterial or viral infections and assess risk of severe illness; conducts therapy response prediction to refine sepsis subtypes and therapy selection; collaborates on drug and device development; and participates in the SUBSPACE Consortium.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inflammatix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NEO New Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NEO New Oncology
2.2 - Growth funds investing in similar companies to NEO New Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NEO New Oncology
4.2 - Public trading comparable groups for NEO New Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →